Venmax Drugs: No Deviation in Preferential Issue Proceeds

Venmax Drugs and Pharmaceuticals Ltd. confirms no deviation or variation in the use of proceeds raised through a preferential issue, as per Regulation 32 of SEBI guidelines. The funds, raised on March 20, 2025, were intended for working capital (₹10 crores) and general corporate purposes/business acquisition (₹10.05 crores). As of March 31, 2026, ₹8.12 crores was utilized for working capital and ₹0.20 crores for general corporate purposes. The Audit Committee reviewed and confirmed the utilization, with no deviations noted by auditors.